Data & Analytics

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

By

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Conflicting polls highlight uncertainty about the public's opinion of pharma

Conflicting polls highlight uncertainty about the public's opinion of pharma

By

Two recent polls paint a complicated picture of the public's opinion of the pharma industry.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

By

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Ponemon: Cybercrime is top cause for healthcare data breaches

Ponemon: Cybercrime is top cause for healthcare data breaches

A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Do We Need Formal Surveys Anymore?

Do We Need Formal Surveys Anymore?

"Social can enable a better starting point to yield better questions and thus make surveys less in number yet greater in value."

Challenges exist, even as excitement grows for big data market

Challenges exist, even as excitement grows for big data market

By

The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

By

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

By

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

By

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Finding the Right Time to Talk to Doctors

Finding the Right Time to Talk to Doctors

Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.

Easy navigation beats out trustworthiness for health info, survey finds

Easy navigation beats out trustworthiness for health info, survey finds

By

Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.

Five things for pharma marketers to know: Tuesday, March 1, 2016

Five things for pharma marketers to know: Tuesday, March 1, 2016

By

Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug

How Obama's Precision Medicine Initiative will Change Healthcare Marketing

How Obama's Precision Medicine Initiative will Change Healthcare Marketing

With these changes coming to healthcare from precision medicine, it may no longer be acceptable to do generic or broad marketing campaigns in hopes of catching the small group of people who may benefit from a device or treatment.

Havas Health partners with data firm to find rare disease patients

Havas Health partners with data firm to find rare disease patients

By

The agency announced a partnership with Vencore Health Analytics to help pair rare disease patients with drugmakers.

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.

Five things for pharma marketers to know: Thursday, December 3, 2015

Five things for pharma marketers to know: Thursday, December 3, 2015

By

Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad

Data Management: Not If, But When

Data Management: Not If, But When

Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage

IMS Health: Drug spend will steadily rise through 2020

IMS Health: Drug spend will steadily rise through 2020

By

Specialty medicines will keep drug spend trending upward through the next five years.

Late-Phase Diabetes Research: Time To Get Onboard

Late-Phase Diabetes Research: Time To Get Onboard

If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.

How IBM's cognitive computing platform might help make healthcare smarter

How IBM's cognitive computing platform might help make healthcare smarter

Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.

Is pharma's access to physicians decreasing or increasing?

Is pharma's access to physicians decreasing or increasing?

By

A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.

Drugmakers spend too much on marketing: Kaiser poll

Drugmakers spend too much on marketing: Kaiser poll

By

The public said drugmakers spend too much money on marketing to doctors and patients

Pharma's acceptance of transparency programs matures as reporting becomes global

Pharma's acceptance of transparency programs matures as reporting becomes global

By

Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.

Five things for pharma marketers to know: Friday, October 23, 2015

Five things for pharma marketers to know: Friday, October 23, 2015

By

Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug

Wearables Create a New World of Data for Clinical R&D

Wearables Create a New World of Data for Clinical R&D

By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.

Bristol-Myers Squibb extends relationship with ZS

Bristol-Myers Squibb extends relationship with ZS

By

The firm is the primary vendor for the drugmaker's global commercial analytics.

Analysis shows pharma is getting better at R&D

Analysis shows pharma is getting better at R&D

By

An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.

Five things for pharma marketers to know: Tuesday, September 22, 2015

Five things for pharma marketers to know: Tuesday, September 22, 2015

By

Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus

OPINION

Email Newsletters